Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

avidity biosciences inc - RNA

RNA

Close Chg Chg %
72.82 0.08 0.11%

Closed Market

72.90

+0.08 (0.11%)

Volume: 3.28M

Last Updated:

Feb 6, 2026, 4:00 PM EDT

Trade Now

Company Overview: avidity biosciences inc - RNA

RNA Key Data

Open

$72.92

 Day Range

72.79 - 72.95

52 Week Range

21.51 - 73.06

 Market Cap

$10.96B

Shares Outstanding

150.75M

 Public Float

138.85M

Beta

0.93

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.17

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.81M

  

RNA Performance

1 Week
 
 0.45%
 
1 Month
 
 0.73%
 
3 Months
 
 4.38%
 
1 Year
 
 108.76%
 
5 Years
 
 224.87%
 

RNA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 12
Full Ratings ➔

About avidity biosciences inc - RNA

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

RNA At a Glance

Avidity Biosciences, Inc.
3020 Callan Road
San Diego, California 92121
Phone 1-858-401-7900 Revenue 10.90M
Industry Biotechnology Net Income -322,302,000.00
Sector Health Technology 2024 Sales Growth 13.985%
Fiscal Year-end 12 / 2025 Employees 391
View SEC Filings

RNA Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 297.77
Price to Book Ratio 2.447
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -4.653
Enterprise Value to Sales 160.605
Total Debt to Enterprise Value 0.004

RNA Efficiency

Revenue/Employee 27,869.565
Income Per Employee -824,301.79
Receivables Turnover N/A
Total Asset Turnover 0.01

RNA Liquidity

Current Ratio 15.735
Quick Ratio 15.735
Cash Ratio 15.319

RNA Profitability

Gross Margin 74.525
Operating Margin -3,477.434
Pretax Margin -2,957.713
Net Margin -2,957.713
Return on Assets -29.401
Return on Equity -33.473
Return on Total Capital -22.511
Return on Invested Capital -33.315

RNA Capital Structure

Total Debt to Total Equity 0.477
Total Debt to Total Capital 0.475
Total Debt to Total Assets 0.435
Long-Term Debt to Equity 0.208
Long-Term Debt to Total Capital 0.207
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Avidity Biosciences Inc - RNA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
9.33M 9.22M 9.56M 10.90M
Sales Growth
+37.41% -1.09% +3.64% +13.99%
Cost of Goods Sold (COGS) incl D&A
639.00K 1.39M 2.10M 2.78M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
639.00K 1.39M 2.10M 2.78M
Depreciation
639.00K 1.39M 2.10M 2.78M
Amortization of Intangibles
- - - -
-
COGS Growth
- +117.06% +51.48% +32.13%
Gross Income
8.69M 7.84M 7.46M 8.12M
Gross Income Growth
- -9.78% -4.82% +8.88%
Gross Profit Margin
+93.15% +84.96% +78.02% +74.53%
2021 2022 2023 2024 5-year trend
SG&A Expense
126.74M 186.75M 243.06M 387.06M
Research & Development
101.18M 150.40M 190.97M 303.59M
Other SG&A
25.56M 36.35M 52.09M 83.46M
SGA Growth
+150.02% +47.35% +30.15% +59.25%
Other Operating Expense
- - - -
-
Unusual Expense
- - - -
-
EBIT after Unusual Expense
(118.05M) (178.91M) (235.60M) (378.94M)
Non Operating Income/Expense
42.00K 4.92M 23.38M 56.63M
Non-Operating Interest Income
104.00K 4.97M 23.97M 56.88M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - -
-
Interest Expense Growth
- - - -100.00%
-
Gross Interest Expense
- - - -
-
Interest Capitalized
- - - -
-
Pretax Income
(118.01M) (174.00M) (212.22M) (322.30M)
Pretax Income Growth
-166.06% -47.44% -21.97% -51.87%
Pretax Margin
-1,265.38% -1,886.33% -2,219.87% -2,957.71%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(118.01M) (174.00M) (212.22M) (322.30M)
Minority Interest Expense
- - - -
-
Net Income
(118.01M) (174.00M) (212.22M) (322.30M)
Net Income Growth
-166.06% -47.44% -21.97% -51.87%
Net Margin Growth
-1,265.38% -1,886.33% -2,219.87% -2,957.71%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(118.01M) (174.00M) (212.22M) (322.30M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(118.01M) (174.00M) (212.22M) (322.30M)
EPS (Basic)
-2.8485 -3.3357 -2.9066 -2.8885
EPS (Basic) Growth
-39.12% -17.10% +12.86% +0.62%
Basic Shares Outstanding
41.43M 52.16M 73.01M 111.58M
EPS (Diluted)
-2.8485 -3.3357 -2.9066 -2.8885
EPS (Diluted) Growth
-39.12% -17.10% +12.86% +0.62%
Diluted Shares Outstanding
41.43M 52.16M 73.01M 111.58M
EBITDA
(117.41M) (177.53M) (233.50M) (376.16M)
EBITDA Growth
-167.43% -51.20% -31.53% -61.10%
EBITDA Margin
-1,258.97% -1,924.61% -2,442.44% -3,451.96%

Snapshot

Average Recommendation HOLD Average Target Price 74.636
Number of Ratings 12 Current Quarters Estimate -1.277
FY Report Date 03 / 2026 Current Year's Estimate -5.091
Last Quarter’s Earnings -1.27 Median PE on CY Estimate N/A
Year Ago Earnings -4.538 Next Fiscal Year Estimate -4.023
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 12 10
Mean Estimate -1.28 -1.31 -5.09 -4.02
High Estimates -0.98 -1.01 -3.92 -1.51
Low Estimate -1.59 -1.61 -6.53 -5.04
Coefficient of Variance -14.64 -14.30 -14.35 -27.21

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 3
OVERWEIGHT 0 0 0
HOLD 10 12 11
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for Avidity Biosciences Inc - RNA

Date Name Shares Transaction Value
Sep 18, 2025 Steven G. Hughes Chief Medical Officer 40,409 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $6.57 per share 265,487.13
Sep 18, 2025 Steven G. Hughes Chief Medical Officer 38,867 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $45.41 per share 1,764,950.47
Sep 18, 2025 Steven G. Hughes Chief Medical Officer 49,333 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Sep 18, 2025 Teresa McCarthy Chief Human Resources Officer 112,130 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $22.34 per share 2,504,984.20
Sep 18, 2025 Teresa McCarthy Chief Human Resources Officer 97,130 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $41.41 per share 4,022,153.30
Sep 18, 2025 Teresa McCarthy Chief Human Resources Officer 85,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 Kathleen Gallagher Chief Program Officer 56,100 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $14.7 per share 824,670.00
Apr 4, 2025 Kathleen Gallagher Chief Program Officer 50,554 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.83 per share 1,406,917.82
Apr 4, 2025 Kathleen Gallagher Chief Program Officer 50,883 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $16.65 per share 847,201.95
Apr 4, 2025 Kathleen Gallagher Chief Program Officer 50,554 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $27.83 per share 1,406,917.82
Apr 4, 2025 Kathleen Gallagher Chief Program Officer 13,829 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Apr 4, 2025 Kathleen Gallagher Chief Program Officer 34,346 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 24, 2025 Sarah Boyce President and CEO; Director 305,871 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $31.06 per share 9,500,353.26
Mar 24, 2025 Michael F. MacLean Chief Financial Officer 96,720 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $31.06 per share 3,004,123.20
Mar 24, 2025 W. Michael Flanagan Chief Scientific Officer 80,195 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $31.06 per share 2,490,856.70

Avidity Biosciences Inc in the News